Immune-based therapies, like immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T cell therapy (CAR-T), have seen increased use in cancer treatment. This has led to cardiovascular adverse events, including myocarditis, pericarditis, vasculitis, thromboembolism, and accelerated atherosclerosis. ICIs impact T cell activation, leading to myocardial inflammation in ICIMy, with combination therapy increasing the risk. CAR-T results in cytokine release from activated T cells and has been associated with cardiotoxicity. Prompt identification and treatment of these cardiovascular irAEs are crucial. Research is ongoing to improve diagnosis, management, and outcomes of cardiovascular events associated with these groundbreaking immunotherapies.
Source link
Cardiovascular toxicity of immune therapies for cancer
